Normal tension glaucoma

Qlaris Bio to Present at Glaucoma 360 New Horizons Forum

Retrieved on: 
Friday, January 27, 2023
Health, Other Science, General Health, Research, Science, Biotechnology, MBA, Syndrome, Blood, Channel modulator, Glaucoma, EVP, NTG, KATP, Htoo, ATP, IOP, FDA, Normal tension glaucoma, Bio, MS, Intraocular pressure, Pharmaceutical industry

Qlaris Bio, Inc. , a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company’s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on Friday, Feb. 3, 2023, at 8:40 a.m. PT (11:40 a.m.

Key Points: 
  • Qlaris Bio, Inc. , a biotechnology company targeting high unmet needs in debilitating ophthalmic diseases, announced today that Thurein Htoo, MS, MBA, the company’s co-founder and chief executive officer, will present during the 12th Annual Glaucoma 360 New Horizons Forum on Friday, Feb. 3, 2023, at 8:40 a.m. PT (11:40 a.m.
  • Htoo will participate in the session titled “Delivering Glaucoma Solutions” and will provide updates on Qlaris Bio’s plans for 2023 and the company’s novel ATP-sensitive potassium (KATP) channel modulator platform currently in development to treat a range of glaucomas, including normal tension glaucoma (NTG), primary open-angle glaucoma (POAG), and glaucoma related to rare diseases such as Sturge-Weber Syndrome.
  • “It is an exciting time for Qlaris and the future of glaucoma therapy,” said Htoo.
  • I am looking forward to sharing updates on Qlaris’ program and our anticipated milestones for the coming year.”
    The Glaucoma 360 New Horizons Forum is hosted by the Glaucoma Research Foundation and brings together clinical, industry, financial, and FDA leaders to discuss research innovation and advances in glaucoma treatment.

Glaucoma Epidemiology Forecasts to 2030: 10 Year Forecasts, 7MM Coverage, Total Prevalent Cases and Glaucoma Patients by Age Group - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Managed care, Health, Blindness, Glaucoma, Ophthalmology, Vision, Organ systems, Normal tension glaucoma, Canine glaucoma

The total diagnosed prevalent population of Glaucoma in the 7MM was 10,104,188 in 2020 , which is expected to increase in the forecast period.

Key Points: 
  • The total diagnosed prevalent population of Glaucoma in the 7MM was 10,104,188 in 2020 , which is expected to increase in the forecast period.
  • Among the European five countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,042,465 cases, followed by Italy and France in 2020.
  • Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalent Population of Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma.

U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma

Retrieved on: 
Tuesday, April 27, 2021
Glaucoma, NicOx, Chemical compounds, Organ systems, Blindness, Vision, Ophthalmology, Cyclopropanes, Ocular hypertension, Intraocular pressure, Normal tension glaucoma, Latanoprost

b'Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma.

Key Points: 
  • b'Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma.
  • Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as VYZULTA\xc2\xae, for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.\nNormal tension glaucoma, also known as low tension or normal pressure glaucoma, is a form of glaucoma in which damage occurs to the optic nerve at intraocular pressure (IOP) within the normal range (less than 21 mmHg).
  • Nicox\xe2\x80\x99s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.
  • The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis.

Canadian Ophthalmological Society aims to reduce blind spots about vision loss during Glaucoma Awareness Month

Retrieved on: 
Monday, January 11, 2021
Ophthalmology, Blindness, Vision, Organ systems, Glaucoma, Intraocular pressure, Optic disc, Visual impairment, Ocular hypertension, Normal tension glaucoma

During Glaucoma Awareness Month, they stress the importance of regular eye exams for detecting glaucoma, given that as much as 40 per cent of vision can be lost without a person noticing it.

Key Points: 
  • During Glaucoma Awareness Month, they stress the importance of regular eye exams for detecting glaucoma, given that as much as 40 per cent of vision can be lost without a person noticing it.
  • "While there currently is no cure, the good news is that vision loss from glaucoma can be prevented through early diagnosis with yearly, comprehensive eye exams."
  • These nerve fibres become damaged by pressure that builds up inside the eye, known as intraocular pressure (IOP), which can cause blind spots and vision loss.
  • The Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care inCanada.

Merck Manuals Shares Key Information on Detecting and Treating Glaucoma

Retrieved on: 
Friday, August 14, 2020
RTT, Ophthalmology, Blindness, Organ systems, Vision, Glaucoma, Optic nerve, Visual impairment, Canine glaucoma, Normal tension glaucoma

Glaucoma is defined as progressive optic nerve damage often associated with increased eye pressure that causes irreversible loss of vision.

Key Points: 
  • Glaucoma is defined as progressive optic nerve damage often associated with increased eye pressure that causes irreversible loss of vision.
  • There are many different types of glaucoma, all with different risk factors and potential treatments.
  • Dr. Rhee compares glaucoma to high blood pressure in that there are no outward symptoms of the condition early on.
  • For more information, visit www.merck.com and connect with us on Twitter , Facebook , Instagram , YouTube and LinkedIn .

Graybug Vision Presents Preclinical Results for GB-401, a Potential Sustained-Delivery Treatment of up to Six Months for Primary Open Angle Glaucoma, at the American Glaucoma Society Annual Meeting

Retrieved on: 
Friday, February 28, 2020
RTT, Ophthalmology, Vision, Blindness, Glaucoma, Senses, Retina, Visual impairment, Eye surgery, Normal tension glaucoma

We are encouraged by these preclinical study results and look forward to evaluating the potential of GB-401 as a new long-term treatment for patients with primary open angle glaucoma in a Phase 1/2a first-in-human trial, said Frederic Guerard, CEO of Graybug Vision.

Key Points: 
  • We are encouraged by these preclinical study results and look forward to evaluating the potential of GB-401 as a new long-term treatment for patients with primary open angle glaucoma in a Phase 1/2a first-in-human trial, said Frederic Guerard, CEO of Graybug Vision.
  • Reducing IOP is the only proven treatment to prevent the progression of vision loss associated with POAG.
  • Our ongoing pharmacokinetic study revealed sustained therapeutic drug levels in the eye from day one to over three months.
  • Graybug Vision is a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve.

Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model

Retrieved on: 
Tuesday, October 15, 2019
Senses, Vision, Perception, Visual system, Glaucoma, Blindness, RTT, Optic nerve, Intraocular pressure, Retina, Normal tension glaucoma, Optic neuropathy

These are important experiments prior to initiating multiple human studies, which we project will be conducted throughout 2020.

Key Points: 
  • These are important experiments prior to initiating multiple human studies, which we project will be conducted throughout 2020.
  • Glaucoma is considered one of the optic neuropathies, indicating that there is damage to the cells that comprise the optic nerve.
  • Currently approved therapies are focused on lowering intraocular pressure (IOP) in order to sustain the nerve fibers and prevent a process of programmed cell death or apoptosis.
  • Current therapies focus on lowering intraocular pressure to help preserve retinal ganglion cells that comprise the optic nerve.

Injectsense Demonstrates Animal-to-Cloud IOP Sensing Pathway for Glaucoma

Retrieved on: 
Wednesday, October 9, 2019
RTT, Blindness, Glaucoma, Ophthalmology, Normal tension glaucoma

The Injectsense IOP-Connect system creates an organ-to-cloud data connection that enables the clinician to assess glaucoma therapy effectiveness at any time.

Key Points: 
  • The Injectsense IOP-Connect system creates an organ-to-cloud data connection that enables the clinician to assess glaucoma therapy effectiveness at any time.
  • The system is expected to provide unprecedented visibility into the IOP profile of the patient over time, and into previously unobserved changes that may affect glaucoma progression.
  • "The product being developed by Injectsense is a game changer in how and when to regulate the treatment of glaucoma.
  • It offers a tangible path to clinically actionable information, enabling new insights into the true relationship between IOP, glaucoma, and therapy effectiveness.

Global Glaucoma treatment Market Forecast to 2023 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 15, 2019
Health, Optical, Pharmaceutical, Blindness, Glaucoma, RTT, Vision, Ophthalmology, Primary juvenile glaucoma, Medicine, Eye surgery, Canine glaucoma, Normal tension glaucoma

The "Global Glaucoma treatment Market Research and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Glaucoma treatment Market Research and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering.
  • The global glaucoma treatment market is emerging with a rapid speed due to some of the major factors such as growing incidences of glaucoma diseases across the globe.
  • The global glaucoma treatment market is studied on the basis of these segments: products, disease indication, end user and drug class.
  • On the basis of disease indication, the market is sub-segmented as closed angle glaucoma, open angle glaucoma, congenital glaucoma and secondary glaucoma.